Leading the Way: Advancing Our Impact in 2024

Since our founding in 1997, The Max Foundation has facilitated access to life-extending medications and care for over 100,000 people living with cancer and critical illness in lower- and middle-income countries. In collaboration with more than 200 institutions worldwide, we delivered 10 million doses to 37,000 people across 83 countries in 2023.

We are proud to highlight our significant impacts of 2024, including:

• Helped over 5,000 NEW patients
• Treated almost 300 women for breast cancer
• Reached 200 patients in our new Chronic Lymphocytic Leukemia (CLL) program
• Expanded our reach into Gambia, Swaziland, and Burundi
• Expanded our diagnostics program to support advanced breast cancer
• Introduced a new third-line treatment for Chronic Myeloid Leukemia (CML) and began treating patients who had no alternative
• Launched a generics pilot program in Kenya to support advanced breast cancer patients
• Extended Day by Day program beyond LatAm into other regions
• Resumed treatment for hundreds in Sudan